Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations.
Hasegawa K, Kagabu M, Mizuno M, Oda K, Aoki D, Mabuchi S, Kamiura S, Yamaguchi S, Aoki Y, Saito T, Yunokawa M, Takehara K, Okamoto A, Ochiai K, Kimura T. Hasegawa K, et al. Among authors: kagabu m. Invest New Drugs. 2017 Dec;35(6):800-812. doi: 10.1007/s10637-017-0504-6. Epub 2017 Sep 2. Invest New Drugs. 2017. PMID: 28864978 Clinical Trial.
A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study).
Shoji T, Takatori E, Omi H, Kagabu M, Honda T, Futagami M, Yokoyama Y, Kaiho M, Tokunaga H, Otsuki T, Takano T, Yaegashi N, Kojimahara T, Ohta T, Nagase S, Soeda S, Watanebe T, Nishiyama H, Sugiyama T. Shoji T, et al. Among authors: kagabu m. Cancer Chemother Pharmacol. 2017 Aug;80(2):355-361. doi: 10.1007/s00280-017-3363-0. Epub 2017 Jun 27. Cancer Chemother Pharmacol. 2017. PMID: 28656383 Free PMC article. Clinical Trial.
A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Primary analysis.
Ishikawa M, Shibata T, Iwata T, Nishio S, Takada T, Suzuki S, Horie K, Kudaka W, Kagabu M, Tanikawa M, Kitagawa R, Takekuma M, Kobayashi H, Yaegashi N; Japan Clinical Oncology Group. Ishikawa M, et al. Among authors: kagabu m. Gynecol Oncol. 2021 Aug;162(2):292-298. doi: 10.1016/j.ygyno.2021.05.007. Epub 2021 May 18. Gynecol Oncol. 2021. PMID: 34016453 Clinical Trial.
Ovarian serous borderline tumors with recurrent or extraovarian lesions: a Japanese, retrospective, multi-institutional, population-based study.
Baba T, Koshiyama M, Kagabu M, Mikami Y, Minamiguchi S, Moritani S, Ishikawa M, Okamoto A, Terao Y, Nakanishi T, Katabuchi H, Tokunaga H, Satoh T, Konishi I, Yaegashi N. Baba T, et al. Among authors: kagabu m. Int J Clin Oncol. 2023 Oct;28(10):1411-1420. doi: 10.1007/s10147-023-02393-z. Epub 2023 Aug 1. Int J Clin Oncol. 2023. PMID: 37526805
High cost of chemotherapy for gynecologic malignancies.
Takahashi N, Seki T, Sasaki K, Machida R, Ishikawa M, Yunokawa M, Matsuoka A, Kagabu M, Yamaguchi S, Hiranuma K, Ohnishi J, Sato T. Takahashi N, et al. Among authors: kagabu m. Jpn J Clin Oncol. 2024 Oct 3;54(10):1078-1083. doi: 10.1093/jjco/hyae089. Jpn J Clin Oncol. 2024. PMID: 39023439
Paclitaxel-carboplatin for advanced or recurrent carcinosarcoma of the uterus: the Japan Uterine Sarcoma Group and Tohoku Gynecologic Cancer Unit Study.
Takano T, Otsuki T, Tokunaga H, Toyoshima M, Utsunomiya H, Nagase S, Niikura H, Ito K, Yaegashi N, Yamada H, Tase T, Kagabu M, Shoji T, Sugiyama T, Sato N, Fujimoto T, Terada Y, Nakahara K, Kurachi H, Yokoyama Y, Mizunuma H, Soeda S, Nishiyama H, Matsumoto T, Sato S, Shimada M, Kigawa J. Takano T, et al. Among authors: kagabu m. Int J Clin Oncol. 2014 Dec;19(6):1052-8. doi: 10.1007/s10147-013-0658-y. Epub 2014 Jan 7. Int J Clin Oncol. 2014. PMID: 24395448 Clinical Trial.
51 results